TMEM106A and central nervous system cancer: Thus, TMEM106A‐high/TP53‐mutant, IDH‐wildtype gliomas represent a rational cohort for mutant‐p53–directed regimens or combinations that integrate PD‐1–axis therapy with p53‐targeted approaches.